A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma-Reference-Cited by-同舟云学术

A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma

Published:2023-07 Issue:14 Volume:15 Page:833-843
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Yin Feng¹^ORCID,Ahsan Farah²,Pinkas Jan¹,Das Biplab¹,Wang Frank¹,Zheng Nancy³,Hahn David³,Amrite Aniruddha¹,Feng Jianwen¹,Adhikari Diana¹,Sikora Jack¹,Shaheen Elizabeth¹,Harriman Shawn¹

Affiliation:

1. Pyxis Oncology, Inc., 321 Harrison Avenue, Suite 1, Boston, MA 02118, USA

2. Q2 Solutions BioSciences LLC, 19 Brown Road, Ithaca, NY 14850, USA

3. Amador Bioscience, Inc., 4695 Chabot Drive, Pleasanton, CA 94588, USA

Abstract

Aim: Aur0101 is a cytotoxic and small-molecule microtubule depolymerizing agent, and is the payload conjugated to antibody–drug conjugate PYX-201. Developing and validating a sensitive bioanalytical method to quantitate Aur0101 was novel and crucial in preclinical PYX-201 studies. Materials & methods: Reference standard Aur0101 and its stable isotope labelled internal standard Aur0101-d8 were used in this LC–MS/MS method. Results: This sensitive assay was validated at a lower limit of quantitation of 15 pg/ml and successfully applied to support preclinical rat and monkey toxicology studies. Preclinical plasma toxicokinetic parameters were presented. Conclusion: A sensitive and robust LC–MS/MS assay was validated for Aur0101 in rat and monkey plasma.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2023-0056

Reference35 articles.

1. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

2. Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

3. Strategies and challenges for the next generation of antibody–drug conjugates

4. Pandit A. Antibody–drug conjugates in oncology: key considerations and future trends (2022). Premier-research.com/blog-antibody-drug-conjugates

5. Axispharm. Antibody–drug conjugates (ADCs) list approved by FDA (2000–2022) (2022). Axispharm.com/antibody-drug-conjugatesadcs-list-approved-by-fda2000-2022